# Ignacio I. Wistuba

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ignacio-i-wistuba/

## Facts

| Field | Value |
| --- | --- |
| Citations | 106,251 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 156 |
| i10-index | 720 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5028085268 |
| ORCID iD | https://orcid.org/0000-0003-3365-6340 |
| Works | 2,825 |

## Researcher papers

Showing 12 of 36.

- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma](https://scholariq.org/papers/i-stk11-lkb1-i-mutations-and-pd-1-inhibitor-resistance-in-i-kras-i-mutant-lung/)
- [PD-L1 as a biomarker of response to immune-checkpoint inhibitors](https://scholariq.org/papers/pd-l1-as-a-biomarker-of-response-to-immune-checkpoint-inhibitors/)
- [Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-advanced-soft-tissue-sarcoma-and-bone-sarcoma-sarc028-a/)
- [An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance](https://scholariq.org/papers/an-epithelial-mesenchymal-transition-gene-signature-predicts-resistance-to-egfr/)
- [Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing](https://scholariq.org/papers/intratumor-heterogeneity-in-localized-lung-adenocarcinomas-delineated-by/)
- [Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression](https://scholariq.org/papers/metastasis-is-regulated-via-microrna-200-zeb1-axis-control-of-tumour-cell-pd-l1/)
- [Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities](https://scholariq.org/papers/patterns-of-transcription-factor-programs-and-immune-pathway-activation-define/)
- [Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities](https://scholariq.org/papers/co-occurring-genomic-alterations-define-major-subsets-of-i-kras-i-mutant-lung/)
- [The BATTLE Trial: Personalizing Therapy for Lung Cancer](https://scholariq.org/papers/the-battle-trial-personalizing-therapy-for-lung-cancer/)
- [Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer](https://scholariq.org/papers/targeting-dna-damage-response-promotes-antitumor-immunity-through-sting-mediated/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.